We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Partnerships Exclusive licenses from Cedars-Sinai Medical Center (endoglin antagonism patents) and license to TRC105/CD105 technologies from Tracon Pharmaceuticals (transferred to Kairos Oct 2025). Phase 2 prostate trial supported by a $3.2M NIH grant to Cedars-Sinai (Dr. Bhowmick) for mechanism-of-action and companion biomarker corollary studies.
Indications
Metastatic castration-resistant prostate cancer (with apalutamide)(Phase 2)
Lung cancer (with Tagrisso/osimertinib, EGFR antagonist resistance)(Phase 1)
Status note Anti-endoglin (CD105) antibody addressing resistance mechanisms: androgen therapy resistance in prostate cancer and EGFR antagonist resistance in lung cancer. Randomized Phase 2 in prostate cancer with apalutamide at Cedars-Sinai, University of Utah and City of Hope; Phase 1 in lung cancer with Tagrisso (AstraZeneca) at Cedars-Sinai. A three-gene companion biomarker panel is being verified in the Phase 2 trial for future patient selection.
ENV205
Stage not disclosed · ActiveModality: biologic
Target circulating mitochondrial DNA
Indications
Chemotherapy-resistant prostate cancer(Stage not disclosed)
Status note Biologic that depletes elevated circulating mitochondrial DNA associated with chemotherapy resistance, cardiac toxicity and systemic inflammatory side effects; designed to restore chemotherapy sensitivity in resistant prostate cancers. Not approved; early-stage development.
KROS101
Stage not disclosed · ActiveModality: small molecule
Target GITR ligand
Indications
Cancer(Stage not disclosed)
Status note Small molecule that induces trimerization of the GITR ligand. Development stage not disclosed.
KROS201
Stage not disclosed · ActiveModality: cell therapy (dendritic cell-stimulated T cells)
Indications
Glioblastoma(Stage not disclosed)
Status note T cells stimulated by dendritic cells in vitro to target cancer stem cells; initial focus glioblastoma. Development stage not disclosed.
KROS102
Stage not disclosed · ActiveModality: small molecule
Target GITR ligand
Indications
Cancer(Stage not disclosed)
Status note GITR ligand antagonist designed to increase inhibitory Treg functions while hampering T effector cell function. Development stage not disclosed.
KROS301
Stage not disclosed · ActiveModality: small molecule
Target RelA (NF-kB)
Indications
Cancer(Stage not disclosed)
Status note Tumor-targeting small molecule and checkpoint inhibitor with two mechanisms via blocking intranuclear localization of RelA (NF-kB pathway); reverses immune suppression at the tumor site. Development stage not disclosed.
KROS401
Stage not disclosed · ActiveModality: peptide
Target IL-4 / IL-13
Indications
Cancer(Stage not disclosed)
Status note Tumor microenvironment immune modulator; cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor-associated macrophage inhibition. Development stage not disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.